Genematrix Begins Phase 1 Trial of Domestically Developed Hepatitis A Vaccine
Predicted impact: Medium
Phase 1 start for a hepatitis A vaccine; early-stage, small company with market value about 29.6 billion won.
Genematrix진매트릭스
109820 · KOSDAQ · ₩109820 · 진매트릭스
₩1,450 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −42.91%
- Market cap
- ₩30B
- Enterprise value
- ₩17B
- P/E
- —
- P/B
- 1.6×
- Dividend yield
- 0.0%
- ROE
- −4.2%
- Net margin
- −6.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−48.1% from the high
₩1,201Today: ₩1,431 – ₩1,490₩2,795
Returns
- 1W−4.0%
- 1M−8.6%
- 3M−0.8%
- 6M−28.7%
- YTD−40.9%
- 1Y−42.9%
- Volume today
- 26,054
- 0.1× the 20-day average
- Traded today
- ₩38M
- Listed shares
- 20,393,640
- EPS (12 months)
- −₩37
- Earnings yield −2.6%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 27 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: A trial start is neutral news, and the management filing gives no detail on its impact. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-8.7% over the last month; the price is below its 20-day average.
- News impactSome2 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Genematrix stock overview
Genematrix (진매트릭스, KRX: 109820) is listed on KOSDAQ, in the Biotech & Pharma sector. , Ltd. Its shares closed at ₩1,450 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩30B.
Key facts
- Market cap
- ₩30B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- , Ltd.
Quick answers about Genematrix
- What does Genematrix do?
- , Ltd. was founded in December 2000 to develop biotechnology-based drugs, including anticancer, antiviral and antibiotic medicines, and diagnostic tests based on gene mutation research. The company develops, manufactures and sells molecular diagnostic kits and biochemical reagents using its proprietary technologies such as C-Tag, Encleap, TriO and RFMP, and is developing vaccines and immuno-oncology treatments.
- What is the market cap of Genematrix?
- The market capitalisation of Genematrix was ₩30B at the close on Oct 27, 2026.
- Who are the largest shareholders of Genematrix?
- According to the latest official filings, the largest reported holders are Kim Su-ok (8.71%, as of Jul 23, 2026); Hong Seon-pyo (3.53%, as of Jul 20, 2026); Kim Seok-jun (3.47%, as of Jul 9, 2026).
- When is the next earnings report from Genematrix?
- Korean companies rarely announce results dates in advance. Based on when Genematrix filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Jinmatrix Co., Ltd. was founded in December 2000 to develop biotechnology-based drugs, including anticancer, antiviral and antibiotic medicines, and diagnostic tests based on gene mutation research. The company develops, manufactures and sells molecular diagnostic kits and biochemical reagents using its proprietary technologies such as C-Tag, Encleap, TriO and RFMP, and is developing vaccines and immuno-oncology treatments. Its main product lines are NeoPlex multiplex tests for sexually transmitted infections, tuberculosis and non-tuberculous mycobacteria, HPV, respiratory infections and gastrointestinal infections, sold mainly through domestic and overseas distributors.
Written by AI from the company's latest annual report.
- Korean name
- 진매트릭스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김수옥
- Founded
- Dec 2000
- Listed
- Nov 2009
- Listed shares
- 20,393,640
- Fiscal year ends
- Month 12
- Website
- www.genematrix.net
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- Amended: Major management matter relevant to investorsOct 27, 2026
- Amended: Half-year report (Jun 2026)Sep 30, 2026
- Added attachment: Half-year report (Jun 2026)Aug 12, 2026
- Insider shareholding reportJul 23, 2026
- Insider shareholding reportJul 20, 2026
Titles in Korean until English translations are added.
Also known as: Genematrix / 진매트릭스 / 109820 / KRX:109820
Source: KRX statistical information